Research Topics
| W ReinischSummaryAffiliation: Medical University of Vienna Country: Austria Publications
| Collaborators
|
Detail Information
Publications
A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitisAlexander Teml
Universitatsklinik fur Innere Medizin IV, Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien, Vienna, Austria
Scand J Gastroenterol 40:1205-13. 2005..The aim of the present study was to evaluate the safety and efficacy of 6-TG in patients with ulcerative colitis (UC) or indeterminate colitis (IC) intolerant or resistant to AZA/6-MP...
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's diseaseW Reinisch
Universitaetsklinik Innere Medizin IV, Abteilung Gastroenterologie and Hepatologie, Vienna, Austria
Gut 55:1138-44. 2006..This study was designed to evaluate the safety of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease (CD)...- Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitisWalter Reinisch
Univ Klinik Innere Medizin IV, AKH Wien, Vienna, Austria, and Division of Gastroenterology, Hospital Leuven, Belgium
Inflamm Bowel Dis 13:1135-40. 2007..Impairment of health-related quality of life, employment, and productivity has been documented in patients with moderate to severe ulcerative colitis... - Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease: An Open-label, Multicenter, Prospective TrialWalter Reinisch
Medical University of Vienna, Vienna, Austria University of Leuven, Leuven, Belgium University of Munich, Munich, Germany LAIR Centre, Vancouver, BC, Canada University of Ulm, Ulm, Germany University of Jena, Jena, Germany Erasmus University, Rotterdam, Netherlands Therakos, Johnson and Johnson, Raritan, New Jersey Mucosal Immunity Section, National Institute of Allergy and Infectious Disease, NIH, Bethesda, Maryland
Inflamm Bowel Dis 19:293-300. 2013..A previous trial demonstrated that ECP permits corticosteroid withdrawal in steroid-dependent Crohn's disease (CD) patients who were in clinical remission. We studied the effect of ECP on steroid withdrawal in steroid-dependent CD... 
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT IW Reinisch
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Austria
Aliment Pharmacol Ther 35:568-76. 2012..Secondary loss of response to anti-TNF-α therapy is observed in Crohn's disease patients...- Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensusWalter Reinisch
University Klinik Innere Medizin III, Abt Gastroenterologie, Vienna, Austria
J Crohns Colitis 6:248-58. 2012..Therefore, it is important to identify which patients are candidates for infliximab therapy... - [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]W Reinisch
AKH Wien, Univ Klinik für Innere Medizin III, Klin Abteilung f Gastroenterologie und Hepatologie, Wien, Osterreich
Z Gastroenterol 49:534-42. 2011..Infliximab is an effective treatment option for the above-mentioned indications; however, use of this agent requires special knowledge to assess the benefit-risk profile for each patient individually... - Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialWalter Reinisch
Medical University Vienna, Vienna, Austria
Gut 60:780-7. 2011.... - Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trialWalter Reinisch
Abteilung Gastroenterologie and Hepatologie, Universitätsklinik für Innere Medizin III, Abteilung Gastroenterologie and Hepatologie, Waehringer Guertel 18 20, A 1090 Vienna, Austria
Gut 59:752-9. 2010..The aim of the study was to compare azathioprine versus mesalazine tablets for the prevention of clinical recurrence in patients with postoperative Crohn's disease (CD) with moderate or severe endoscopic recurrence... - "How to manage loss of response to anti-TNF in Crohn's disease? "Walter Reinisch
Universitätsklinik Innere Medizin III, Abteilung Gastroenterologie und Hepatologie, Waehringer Guertel 18 20, A 1090 Vienna, Austria
Curr Drug Targets 11:152-5. 2010..The molecular mechanisms of loss of response are not fully understood, but clinician face this clinical problem. The aim of this paper is to review the clinical strategies to face anti-TNF alpha antibodies in Crohn' disease... - Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose studyWalter Reinisch
Clinic of Internal Medicine III, Department of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
Inflamm Bowel Dis 16:233-42. 2010..Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptoms... - [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology]W Reinisch
Medizinische Universität Wien, Univ Klinik Innere Medizin III, Waehringer Guertel 18 20, 1090 Wien, Osterreich
Z Gastroenterol 47:372-80. 2009..The presented therapy guidelines based on existing evidence are aimed to assist in the efficient and safe use of adalimumab in the treatment of Crohn's disease... - Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studiesWalter Reinisch
Department of Gastroenterology and Hepatology, Univ Klinik Innere Medizin III, AKH Wien, Vienna, Austria
Inflamm Bowel Dis 18:201-11. 2012..The aim was to evaluate long-term efficacy, quality of life, and safety in ulcerative colitis patients who received infliximab during the ACT-1 and -2 extension studies... - [Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD]W Reinisch
Univ.-Klinik f. Innere Medizin IV, Abteilung Gastroenterologie und Hepatologie, AKH Wien, Austria
Z Gastroenterol 42:1033-45; discussion 1046-7. 2004..The risk of malignancy using immunosuppressive drugs such as AZA is low and furthermore, especially AZA and 6-MP can be used rather safely during pregnancy... - In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel diseaseC Dejaco
Department of Internal Medicine IV, University of Vienna, Austria
J Investig Med 48:449-56. 2000..The present study investigates the in vivo immunomodulatory properties of rHuIL-10 in inflammatory bowel disease (IBD)... - A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseW Miehsler
Department of Internal Medicine 3, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria
J Crohns Colitis 4:221-56. 2010..Both parts are further divided into obligatory and facultative items... - Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?W Miehsler
Department of Internal Medicine IV, University of Vienna, Austria
Am J Gastroenterol 96:782-7. 2001..The aim of the present study was to investigate the effect of MMF, especially in AZA-intolerant patients with chronic active CD, in comparison to a matched control group treated with AZA... - Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's diseaseC Dejaco
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Institute of Tumour Biology, University Hospital, Vienna, Austria
Aliment Pharmacol Ther 18:1113-20. 2003..CONCLUSION: Antibiotics are useful to induce a short-term response in perianal Crohn's disease, and may provide a bridging strategy to azathioprine, which seems to be essential for the maintenance of fistula improvement... - IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel diseaseC Gasche
Department of Gastroenterology and Hepatology, University of Vienna, Austria
J Clin Immunol 20:362-70. 2000..Our data suggest that LPMC derived from inflamed colonic mucosa have a reduced ability to produce and to respond to rhIL-10. A disease-specific alteration in the IL-10 pathway, however, was not found... - [Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party]C Gasche
Medizinische Universität Wien, Klinik Innere Medizin 3, Abteilung Gastroenterologie und Hepatologie
Z Gastroenterol 49:627-32. 2011..The clinical importance of intravenous iron replacement therapy in IBD with regard to effectiveness and compliance was discussed... - Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?W Miehsler
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
Gut 53:542-8. 2004..However, the extent of this risk is not known. Furthermore, it is not known if this risk is specific for IBD or if it is shared by other chronic inflammatory diseases or other chronic bowel diseases... - Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot studyW Reinisch
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Austria
Aliment Pharmacol Ther 15:1313-22. 2001..Extracorporeal photochemotherapy has been proven effective in selected T-cell mediated diseases... - The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's diseaseA Eser
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria
Aliment Pharmacol Ther 35:292-9. 2012..Antibodies to Saccharomyces cerevisiae (ASCA) are highly prevalent in sera of patients with Crohn's disease and have been proposed to identify subgroups of patients with a disabling disease course... - Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytesM Willheim
Institute of General and Experimental Pathology, Clinic of Internal Medicine IV, University of Vienna, Austria
J Clin Endocrinol Metab 84:3739-44. 1999..The influence of 1alpha,25-(OH)2D3 on cytokine production by lymphocytes is probably an important point of intersection between the endocrine and the immune system... - Infliximab: lack of efficacy on perforating complications in Crohn's diseaseWolfgang Miehsler
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
Inflamm Bowel Dis 10:36-40. 2004..However, little knowledge exists about its use for the treatment of internal fistulas in CD. We present our experience with infliximab in this situation... - Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitorsP Papay
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
Aliment Pharmacol Ther 36:858-65. 2012..Patients treated with TNF-α inhibitors (TNFi) are at high risk of reactivation of latent tuberculosis (LTB). Prospective studies on monitoring of TB reactivation and/or infection in this risk group are lacking... - Anti-Gal titers in healthy adults and inflammatory bowel disease patientsA Mangold
Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
Transplant Proc 43:3964-8. 2011..Furthermore, we hypothesized that inflammatory bowel disease (IBD) patients display increased anti-Gal titers... - Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease stricturesA Ferlitsch
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
Endoscopy 38:483-7. 2006..However, recurrent symptoms frequently make it necessary to repeat the procedure... - Azathioprine treatment and male fertility in inflammatory bowel diseaseC Dejaco
Division of Gastroenterology and Hepatology, Department of Internal Medicine IV, Institute of Tumor Biology, Vienna, Austria
Gastroenterology 121:1048-53. 2001..During the study period, 6 patients fathered 7 healthy children. CONCLUSIONS: Our data show that AZA does not reduce semen quality and thereby male fertility in IBD... - The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgeryPavol Papay
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
Am J Gastroenterol 105:1158-64. 2010..Good evidence for the latter is lacking. The objective of this study was to evaluate the impact of thiopurine treatment on surgical recurrence in patients after first intestinal resection for CD and its possible interaction with smoking... - Donor dependent, interferon-gamma induced HLA-DR expression on human neutrophils in vivoW Reinisch
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Centre of Molecular Medicine of the Austrian Academy of Sciences, University of Vienna, Vienna, Austria
Clin Exp Immunol 133:476-84. 2003..Due to their abundance in inflammatory reactions heterogeneous HLA-DR expression by neutrophils could determine the outcome of superantigen-driven diseases... - Extracorporeal photopheresis: past, present, and futureRobert Knobler
Department of Dermatology, Medical University of Vienna, Vienna, Austria
J Am Acad Dermatol 61:652-65. 2009..Progress is also being made in the search for understanding of the mechanisms of action of ECP, which will ultimately facilitate improvements in the use of this therapy... - A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's diseaseWalter Reinisch
Universitaetsklinik für Innere Medizin IV, Vienna, Austria
Am J Gastroenterol 103:2284-92. 2008..A prospective study was undertaken to compare the efficacy of everolimus versus azathioprine or placebo in maintaining steroid-induced remission in active Crohn's disease (CD) and assess the safety and pharmacokinetics of everolimus... - Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopyJohannes Sailer
Department of Radiology, Medical University of Vienna, Vienna, Austria
Eur Radiol 18:2512-21. 2008..1% (kappa 0.84). MR enteroclysis allows assessment of Crohn's disease recurrence after ileocolic resection. The MR score is reproducible and shows high agreement with the approved endoscopic Rutgeerts score... - Which patients with IBD need psychological interventions? A controlled studyWolfgang Miehsler
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, University of Vienna, Austria
Inflamm Bowel Dis 14:1273-80. 2008..Whether there is a need for psychological interventions is unknown. This study investigated the quantity and quality of the need for psychological interventions in IBD as compared to rheumatoid arthritis (RA)... - Inflammatory bowel disease is a risk factor for recurrent venous thromboembolismGottfried Novacek
Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Gastroenterology 139:779-87, 787.e1. 2010..We performed a cohort study to determine the risk for recurrent VTE among patients with IBD compared with subjects without IBD... - Diagnostic value of CT enteroclysis compared with conventional enteroclysis in patients with Crohn's diseaseJohannes Sailer
Department of Radiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
AJR Am J Roentgenol 185:1575-81. 2005..The objective of our study was to assess the diagnostic value of CT enteroclysis compared with conventional enteroclysis in patients with Crohn's disease... - Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's diseaseGottfried Novacek
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna A 1090, Austria
World J Gastroenterol 12:6026-31. 2006..To evaluate the effect of resistance to activated protein C (aPCR), the most common known inherited thrombophilic disorder, on the risk of intestinal operation of fibrostenosis in patients with Crohn's disease (CD)... - Effects of trovafloxacin on the IL-1-dependent activation of E-selectin in human endothelial cells in vitroS M Zakeri
Department of Internal Medicine IV, University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
Immunopharmacology 48:27-34. 2000..These data provide evidence that accumulation of high concentration of trova in vivo in inflamed tissue might alter inflammatory responses... - An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgiaW Reinisch
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
Aliment Pharmacol Ther 17:1371-80. 2003..The promising safety and efficacy profile warrants further evaluation in controlled trials... - Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide librariesE Jensen-Jarolim
Department of Pathophysiology, University of Vienna, Austria
J Clin Immunol 21:348-56. 2001..Our data may suggest that galectin-3 mimotopes could be used for the induction of IgG with desired specificity to regulate immune responses in Crohn's disease patients... - Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatmentAlexander Teml
, , , , Vienna, Austria
Am J Gastroenterol 98:2226-31. 2003..CONCLUSIONS: ASCA are stable markers during steroid and mesalamine treatment, highlighting their reliability for use in diagnosis of CD... - An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's diseaseClemens Dejaco
Division of Gastroenterology and Hepatology, Department of Internal Medicine IV, University Hospital of Vienna, Vienna, Austria
Digestion 68:63-70. 2003..We performed a prospective, open-label pilot study with rhG-CSF for the treatment of CD... - Sexual function and quality of life after surgical treatment for anal fistulas in Crohn's diseaseS Riss
Department of General Surgery, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
Tech Coloproctol 17:89-94. 2013..The aim of this study was to assess sexual function and quality of life (QoL) in patients after surgery for perianal Crohn's disease... - [Probiotics for the prevention of antibiotic-induced diarrhea]A Eser
Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Osterreich
Z Gastroenterol 50:1089-95. 2012..Based on their efficacy and clinical data, different levels of evidence and recommendations are emerging on the preventive use of probiotics in antibiotic-associated diarrhoea... - Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha productionChristoph Gasche
Department of Medicine 4, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
J Immunol 170:5578-82. 2003..In addition, these IL-10R1 variants had no influence on the IL-10R1 expression density. Structural analysis of the S138G variant revealed that the substitution of S138G may interfere with binding of IL-10 to IL-10R1... - NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's diseaseSieglinde Angelberger
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria
Am J Gastroenterol 103:1197-202. 2008..The aim of the study was to explore systematically the association between NOD2/CARD15 variants and clinical response of perianal fistulas in patients using antibiotic therapy... - Assessing the demand for psychological care in chronic diseases: development and validation of a questionnaire based on the example of inflammatory bowel diseaseWolfgang Miehsler
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Austria
Inflamm Bowel Dis 10:637-45. 2004.... - Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinomaWalter Reinisch
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
J Immunother 25:489-99. 2002..Immunotherapeutic approaches hold promise to prolong survival in selected patients with advanced HCC who respond by enhanced tumor immunogenicity... - Heterogeneous expression and regulation of CD40 in human hepatocellular carcinomaMargareta Holub
Department of Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Eur J Gastroenterol Hepatol 15:119-26. 2003..The lack of detectable effects of CD40 ligation does not support a major role of this molecule in hepatocellular carcinoma biology... - 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertensionArnulf Ferlitsch
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
Am J Gastroenterol 102:2495-503. 2007..An influence of 6-TG on portal pressure remains to be determined. The aim of the study was to examine the functional relevance of long-term 6-TG treatment on hepatic hemodynamics in IBD patients and its association with NRH... - Impact of interobserver disagreement on phenotype-genotype associations in Crohn's diseaseAnna Oefferlbauer Ernst
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
Inflamm Bowel Dis 13:156-63. 2007..We determined interobserver agreement on applications of definitions of the Vienna Classification variables and computed the potential influence of misclassification on genotype/phenotype associations... - Expression of the high-affinity IgG receptor FcRI (CD64) in patients with inflammatory bowel disease: a new biomarker for gastroenterologic diagnosticsWolfgang Tillinger
1st Medical Department, Hietzing Hospital, Wolkersbergenstrasse 1, Vienna, Austria
Am J Gastroenterol 104:102-9. 2009.... - Infliximab for induction and maintenance therapy for ulcerative colitisPaul Rutgeerts
University Hospital Gasthuisberg, Leuven, Belgium
N Engl J Med 353:2462-76. 2005..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis... - The effects of infliximab therapy on health-related quality of life in ulcerative colitis patientsBrian G Feagan
Robarts Research Institute, University of Western Ontario, London, Canada
Am J Gastroenterol 102:794-802. 2007..The impact of infliximab induction and maintenance therapy on health-related quality of life (HRQL) was evaluated in patients with ulcerative colitis (UC)... - Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-upHeimo H Wenzl
Department of Internal Medicine, Karl-Franzens University Graz, Austria
Eur J Gastroenterol Hepatol 16:767-73. 2004..A substantial subgroup of patients appear to have a prolonged benefit from infliximab therapy... - Steroid dependency in Crohn's diseaseWalter Reinisch
Gastroenterology 123:393-5; author reply 395. 2002 - The value of serologic markers in indeterminate colitis: a prospective follow-up studySofie Joossens
Gastroenterology Unit, Department of Pathology, U.Z. Gasthuisberg, Leuven, Belgium
Gastroenterology 122:1242-7. 2002..6%. Interestingly, 48.5% of patients do not show antibodies against ASCA or pANCA. Most of these patients remain diagnosed with IC during their further clinical course, perhaps reflecting a distinct clinicoserological entity... - Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease?Marieluise Harrer
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University Clinic of Vienna, Austria
Eur J Gastroenterol Hepatol 15:1281-5. 2003.... - [NOD2/CARD15 mutations and genotype-phenotype correlations in patients with Crohn's disease. Hungarian multicenter study]Laszlo Lakatos
Csolnoky Ferenc Kórház, I Sz Belgyógyászati Osztály, Veszprem
Orv Hetil 145:1403-11. 2004..It has also been suggested that the presence of mutation may influence the phenotype of the disease. The aim of this study was to determine the frequency of common NOD2/CARD15 mutations in Hungarian Crohn's patients... - Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlationsPeter Laszlo Lakatos
1st Department of Medicine, Semmelweis University, Koranyi str 2 A, H 1083, Hungary
World J Gastroenterol 11:1489-95. 2005..To determine common NOD2/CARD15 mutations and TLR4 D299G polymorphism in Hungarian patients with CD... - A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colonKlaus Fellermann
Department of Internal Medicine I, Robert Bosch Hospital, 70376 Stuttgart, Germany
Am J Hum Genet 79:439-48. 2006..033). In conclusion, a lower HBD-2 gene copy number in the beta-defensin locus predisposes to colonic CD, most likely through diminished beta-defensin expression... - Complications in Crohn's disease: right-sided ureteric stenosis and hydronephrosisSieglinde Angelberger
Inflamm Bowel Dis 13:1056-7. 2007